Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Baxter Healthcare Corporation
ClinicalTrials.gov Identifier:
NCT00916032
First received: June 5, 2009
Last updated: September 3, 2013
Last verified: September 2013

June 5, 2009
September 3, 2013
June 2009
April 2010   (final data collection date for primary outcome measure)
  • Area Under the Plasma Concentration Versus Time Curve From 0 to 48 Hours (AUC 0-48h). Chromogenic Assay [ Time Frame: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours. ] [ Designated as safety issue: No ]
    Computed using the linear trapezoidal method.
  • Area Under the Plasma Concentration Versus Time Curve From 0 to 48 Hours (AUC 0-48h). One-stage Activated Partial Thromboplastin Time (aPTT) Assay [ Time Frame: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours. ] [ Designated as safety issue: No ]
    Computed using the linear trapezoidal method.
The primary endpoint is the area under the plasma concentration versus time curve from 0 to 48 hours. [ Time Frame: 48 hours post-infusion ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00916032 on ClinicalTrials.gov Archive Site
  • Area Under the Plasma Concentration Versus Time Curve From 0 to Infinity (AUC 0-infinity). Chromogenic Assay [ Time Frame: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours. ] [ Designated as safety issue: No ]
    The total area under the plasma concentration versus time curve when the concentration is extrapolated to zero using the slope of the β-phase of the model.
  • Area Under the Plasma Concentration Versus Time Curve From 0 to Infinity (AUC 0-infinity). One-stage aPTT Assay [ Time Frame: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours. ] [ Designated as safety issue: No ]
    The total area under the plasma concentration versus time curve when the concentration is extrapolated to zero using the slope of the β-phase of the model.
  • Incremental Recovery at Cmax - Chromogenic Assay [ Time Frame: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3 hours. ] [ Designated as safety issue: No ]
    Determined as the highest Factor VIII (FVIII) activity achieved post-infusion
  • Incremental Recovery at Cmax - One-stage aPTT Assay [ Time Frame: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3 hours. ] [ Designated as safety issue: No ]
    Determined as the highest FVIII activity achieved post-infusion
  • Incremental Recovery at 30 Minutes- Chromogenic Assay [ Time Frame: 30 minutes pre-infusion and 30 minutes post-infusion ] [ Designated as safety issue: No ]
    Change in factor VIII concentration from pre-infusion to 30 minutes post-infusion
  • Incremental Recovery at 30 Minutes- One-stage aPTT Assay [ Time Frame: 30 minutes pre-infusion and 30 minutes post-infusion ] [ Designated as safety issue: No ]
    Change in factor VIII concentration from pre-infusion to 30 minutes post-infusion
  • Elimination Phase Half-life- Chromogenic Assay [ Time Frame: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours. ] [ Designated as safety issue: No ]
    calculated as log_e2/λ, where λ is the regression slope in the terminal phase of the least absolute deviations regression model
  • Elimination Phase Half-life- One-stage aPTT Assay [ Time Frame: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours. ] [ Designated as safety issue: No ]
    calculated as log_e2/λ, where λ is the regression slope in the terminal phase of the least absolute deviations regression model
  • FVIII Clearance- Chromogenic Assay [ Time Frame: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours. ] [ Designated as safety issue: No ]
    computed as the dose divided by total AUC
  • FVIII Clearance- One-stage aPTT Assay [ Time Frame: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours. ] [ Designated as safety issue: No ]
    Computed as the dose divided by total AUC
  • Mean Residence Time (MRT)- Chromogenic Assay [ Time Frame: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours. ] [ Designated as safety issue: No ]
    Computed as total area under the first moment curve (Total AUMC) divided by the total area under the concentration versus time curve (Total AUC)
  • Mean Residence Time (MRT)- One-stage aPTT Assay [ Time Frame: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours. ] [ Designated as safety issue: No ]
    Computed as total area under the first moment curve (Total AUMC) divided by the total area under the concentration versus time curve (Total AUC)
  • Volume of Distribution at Steady State- Chromogenic Assay [ Time Frame: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours. ] [ Designated as safety issue: No ]
    computed as Clearance (CL) * Mean residence time (MRT)
  • Volume of Distribution at Steady State- One-stage aPTT Assay [ Time Frame: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours. ] [ Designated as safety issue: No ]
    computed as CL * MRT
  • Factor VIII (FVIII) Maximum Plasma Concentration (C-max)- Chromogenic Assay [ Time Frame: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours. ] [ Designated as safety issue: No ]
    Determined as the highest FVIII activity achieved post-infusion.
  • Factor VIII (FVIII) Maximum Plasma Concentration (C-max)- One-stage aPTT Assay [ Time Frame: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours. ] [ Designated as safety issue: No ]
    Determined as the highest FVIII activity achieved post-infusion.
Not Provided
Not Provided
Not Provided
 
Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A
Pharmacokinetic Comparison of 3000 IU Advate (rAHF-PFM) (Using One 3000 IU Potency Vial) With 3000 IU Advate (rAHF PFM) (Using Two 1500 IU Potency Vials) in Previously Treated Patients With Severe Hemophilia A: a Phase 4, Open-label, Prospective, Randomized, Controlled, Crossover, Multiple Center Study

The objective of this clinical study is to compare the pharmacokinetic parameters of 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent with that of 3000 IU Advate using two vials of 1500 IU potency dissolved in 5 mL diluent each (administered in 10 mL diluent in total) in previously treated patients with severe hemophilia A (factor VIII level < 1%).

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Hemophilia A
Biological: Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]
Participants will receive 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent followed by two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total) or the alternate sequence
Other Names:
  • ADVATE
  • Antihemophilic Factor (Recombinant)- Plasma/albumin free method (rAHF-PFM)
  • Active Comparator: 1
    One infusion using a 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent followed by a second infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total)
    Intervention: Biological: Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]
  • Active Comparator: 2
    One infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total) followed by a second infusion of one 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent
    Intervention: Biological: Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
29
April 2010
April 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Participant is 18 to 65 years old, at the time of screening
  • Participant has provided signed informed consent
  • Participant has severe hemophilia A, defined by a baseline FVIII level < 1% of normal, as tested at screening at the central laboratory
  • Participant's weight is between 55-65 kg
  • Participant was previously treated with FVIII concentrate(s) for a minimum of 150 exposure days prior to study entry
  • If Participant is HIV positive, he must be immunocompetent as determined with a CD4 count ≥ 200 cells/mm³ (CD4 count at screening)
  • Participant is willing and able to comply with the requirements of the protocol

Exclusion Criteria:

  • Participant has a detectable FVIII inhibitor at screening, with a titer ≥ 0.4 Bethesda unit (BU) (Nijmegen modification of the Bethesda Assay) measured at the central laboratory
  • Participant has a history of FVIII inhibitors with a titer ≥ 0.4 BU (by Nijmegen assay) or ≥ 0.5 BU (by Bethesda Assay) at any time prior to screening
  • Participant has undergone a surgery within 21 days prior to screening or within 6 weeks prior to the anticipated first pharmacokinetics(PK) infusion
  • Participant has an abnormal renal function (serum creatinine > 1.5 mg/dL)
  • Participant has active hepatic disease (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels >5 times the upper limit of normal)
  • Participant has severe chronic liver disease as evidenced by, but not limited to, any of the following: International Normalized Ratio (INR) > 1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly, and history of esophageal varices
  • Participant has clinical and/or laboratory evidence of abnormal hemostasis from causes other than hemophilia A (eg, late-stage chronic liver disease, immune thrombocytopenia purpura)
  • Participant is currently receiving, or is scheduled to receive during the course of the clinical study, an immunomodulating drug other than anti-retroviral chemotherapy (eg, alfa-interferon, or corticosteroid agents at a dose equivalent to hydrocortisone greater than 10 mg/day)
  • Participant has a known hypersensitivity to mouse or hamster proteins
  • Participant has participated in another clinical study involving an investigational product or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an investigational product or investigational device during the course of this clinical study
  • Participant is identified by the investigator as being unable or unwilling to cooperate with study procedures
  • Participant is a member of the team conducting this clinical study or is in a dependent relationship with one of the study team members. Dependent relationships include close relatives (ie, children, partner/spouse, siblings, or parents) as well as employees of the investigator or site personnel conducting the clinical study.
Male
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Bulgaria,   Russian Federation
 
NCT00916032
060801
Yes
Baxter Healthcare Corporation
Baxter Healthcare Corporation
Not Provided
Study Director: Baxter Bio Science Investigator Baxter Healthcare Corporation
Baxter Healthcare Corporation
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP